Leased Therapeutics key, A biotech company specialized in genome editing today has announced that it has collected a total of $ 2.62 million to accelerate the development of its re -based genome editing technology.
The French Biotech-Centric Fund IXLIFE Capital VC Group has increased the € 900K capital with the help of Ventures, family companies and business angels. Investment through Win 4 Company Program from the Ministry of Research of Walonia is a public initiative supporting innovative agencies in the Walun region of Belgium.
“Editing the genome keeps a lot of promises in the treatment of rare and complex genetic disorders. In Queiditas, our goal is to push its border to a definite and adaptive solution that can solve potential treatment needs“Said Franois CherbonauCEO and co-founder of QDT. “We are grateful for the investors for supporting us to take us a step forward to make our view of healthcare change through genomic medicine. We also want to thank the Walun region as well, because this grant will help strengthen Belgium’s role as the main player of European Biotech innovation and biopadocationThe “
Established in 2022, Quididas is a biotech company that develops a specific and adapted genome editing platform with gene therapy, protein biopodation and multiple applications across regenerative drugs.
The company was established by Franois Cherbonau, PhD, MNG and PhD, PhD, MNG, two biotechnologists who were founded by the Paris Saint-Lewis Hospital (France) and Boston Massachusetts General Hospital/Harvard Medical School (US). Their doctoral thecees concentrated on molecular genetics and biotechnology research projects in immunology.
Enables large, high-laxed genetic changes, the goal of Quaditus is to convert and create the gene therapy field “Fancy treatment which was out of reach for a long time for certain conditions“.
Its method can be used to address complex and rare diseases through gene therapy, as well as opening new opportunities in biopoduction, stem cell research and other biomedical cases.
“IAccepted to organizations who are able to revolutionize the Exceliff Biotech space“Said Gin-pierMD, Managing Partner of IXLife Capital, Immunologist and Emeritus Professor of Harvard Medical School. “The genome editing technology of Quaditus represents a converter of the field in front, with some challenging diseases to be resolved. We are interested in supporting missions to bring effective solutions to patientsThe “
Even in the genome editing and gene therapy sector, even in the treatment of CRISPR genetic diseases, the use of this technology is still obstructed by technical problems such as skills and specifics, and its effectiveness is in accordance with the comments of the DNA reconnection by the comments of the Coeditus.
The goal of Queeditus’s technology is to fill this gap and bring the gene therapy to the next level.
It can cut any single or double stranded nucleic acid sequences (RNA or DNA) and can prevent any length of nucleic acid anywhere in the genome in a completely controlled manner. It can replace a whole gene or exen by cutting a selected sequence and adding one more to the double stuck. This technology is not only versatile, but bypasses current technical limitations, creating a complete gene reconnection.
[publish_date
